Clinical Pharmacy Specialist: Infectious Diseases
About the job
- A Doctor of Pharmacy degree is required.
- Completion of a PGY-1 Pharmacy Residency plus at least three years of hospital practice, completion of a PGY-2 Pharmacy Residency (Infectious Diseases preferred), or at least five years of hospital clinical practice experience is required.
- Eligibility for Florida pharmacy licensure is required.
- Collaborate with Infectious Diseases physicians and multidisciplinary teams to optimize antimicrobial therapy for complex hospitalized patients.
- Perform prospective audit and feedback activities, including review of bloodstream infections, antimicrobial stewardship worklists, restricted antimicrobial utilization, broad-spectrum antibiotic therapy, HIV/antiretroviral therapy, and other targeted stewardship initiatives.
- Participate in Infectious Diseases Consult Service rounds with ID attendings and fellows, providing evidence-based recommendations regarding antimicrobial initiation, optimization, de-escalation, duration of therapy, and diagnostic stewardship.
- Support the development, implementation, and maintenance of antimicrobial stewardship initiatives, protocols, clinical pathways, order sets, guidelines, and quality improvement projects.
- Analyze antimicrobial utilization and resistance data, participate in developing annual antibiograms, and identify opportunities to improve clinical outcomes and antimicrobial utilization.
- Collaborate with Infection Prevention, Microbiology, Sepsis, Quality, and Clinical Operations teams on system-wide initiatives focused on improving patient outcomes and reducing antimicrobial resistance.
- Participate in multidisciplinary and corporate committees, including antimicrobial stewardship, medication-use, infection prevention, microbiology, sepsis, and quality-improvement initiatives.
- Serve as a mentor and infectious diseases resource for a growing decentralized clinical pharmacy staff.
- Precept pharmacy residents and students in infectious diseases and antimicrobial stewardship learning experiences.
- Participate in clinical research, medication-use evaluations, and scholarly activities related to infectious diseases and antimicrobial stewardship.
- Provide education to pharmacists, physicians, nurses, residents, fellows, and students.
- Board Certification in Infectious Diseases Pharmacy (BCIDP) is preferred, or eligibility with a commitment to obtain certification.
- Completion of a PGY-2 Pharmacy Residency in Infectious Diseases is preferred.
About the company
Orlando Health is a not-for-profit healthcare system that runs hospitals, clinics, and other health services in the southeastern United States. It coordinates care through its network of facilities and clinicians, combining inpatient and outpatient services to provide medical treatment and preventive care. It stands out from competitors by being not-for-profit, with a long history and a regional focus that allows reinvesting earnings into local health initiatives rather than distributing profits to shareholders. Its goal is to improve community health by delivering high-quality, accessible care and using surplus funds to expand services and support community benefits.
Company Size
N/A
Company Stage
N/A
Total Funding
$250.5M
Headquarters
Orlando, Florida
Founded
1918
Get referred to Orlando Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- RMC Health System acquisition adds 375 beds and 2,000 employees in Alabama.
- Orlando Health Watson Clinic Lakeland Highlands Hospital opens in June 2026.
- Institute Square opened in St. Petersburg with Florida Cancer Specialists and on-site PET/CT.
What critics are saying
- Fiscal 2025 operating margin fell to 3.5% after acquisition-driven expense growth.
- The Rockledge closure triggered 900 layoffs and demolition plans across Brevard County.
- Website-tracking litigation signaled class-action exposure across Orlando Health's digital front door.
What makes Orlando Health unique
- Orlando Health built a $10 billion multi-state system through aggressive hospital acquisitions.
- Its Institute Square combines cancer, orthopedics, and women’s care under one campus.
- Watson Clinic and FCS partnerships deepen physician alignment without full mergers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Student Loan Assistance
Tuition Reimbursement
Family Planning Benefits
Company News
Florida Cancer Specialists & Research Institute has opened a new 31,000-square-foot facility at Orlando Health Institute Square in St. Petersburg, expanding cancer care access in Pinellas County. The location at 725 6th Ave South features 18 private exam rooms, 47 infusion chairs and on-site PET/CT imaging. The facility offers advanced treatments including bispecific therapies and clinical trial participation, with plans to expand outpatient cell therapy programmes. Six board-certified medical oncologists and haematologists, supported by four advanced practice practitioners, provide care through a collaborative, patient-centred model. The opening represents a hospital-specialty collaboration aimed at bringing complex therapies closer to patients' homes. FCS operates six other locations in Pinellas County and has delivered oncology care in Florida for over 40 years.
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis ...
Gainesville, FL – 8/18/2025 – Orthopedic Driven Imaging (ODI), a medical technology company building the next generation of orthopedic imaging solutions, announced today a strategic investment from the Innovation Center at Orlando Health Jewett Orthopedic Institute. The investment supports ODI’s mission to simplify surgery and improve outcomes through a unique ecosystem of imaging hardware and […]
BIRMINGHAM, Ala. (WIAT) — Orlando Health, Inc. has signed an agreement to purchase majority interest in Brookwood Baptist Health. According to a news release from Orlando Health, they will ma…
BioStable Science & Engineering announces the initial closing of its Series C financing